Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.62 |
| ▸ | ABL1 | P00519 | 11/20 | 0.62 |
| ▸ | KIT | P10721 | 8/20 | 0.62 |
| ▸ | BCR | P11274 | 8/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.57 |
| ▸ | ABL2 | P42684 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551029 | 0.92 | PDGFRA (0.58) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL24251081 | 0.92 | PDGFRA (0.58) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL29551405 | 0.91 | PDGFRA (0.77) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL24250931 | 0.91 | PDGFRA (0.77) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL24250962 | 0.87 | PDGFRA (0.69) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL29551818 | 0.87 | PDGFRA (0.69) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL24250999 | 0.87 | PDGFRA (0.65) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL24251073 | 0.84 | PDGFRA (0.62) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL24250948 | 0.83 | PDGFRA (0.61) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL4882244 | 0.81 | ABL1 (0.83) | PDGFRAABL1KITBCRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | PDGFRA 145/4885ABL1 695/4885KIT 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.